Patent ID: 7514081

Claim:
A method of inhibiting an inflammatory immune response in a subject, comprising administering to the subject an effective amount of an isolated antibody or an antigen-binding fragment thereof that binds to a protein consisting of an amino acid sequence selected from the group consisting of: (a) amino acids 1 to 169 of SEQ ID NO:2; (b) amino acids 2 to 169 of SEQ ID NO:2; (c) amino acids 1 to 17 of SEQ ID NO:2; (d) amino acids 18 to 43 of SEQ ID NO:2; (e) amino acids 44 to 169 of SEQ ID NO:2; (f) amino acids 44 to 158 of SEQ ID NO:2; (g) amino acids 44 to 54 of SEQ ID NO:2; (h) amino acids 57 to 68 of SEQ ID NO:2; (i) amino acids 69 to 78 of SEQ ID NO:2; (j) amino acids 94 to 105 of SEQ ID NO:2; (k) amino acids 108 to 132 of SEQ ID NO:2; (l) amino acids 148 to 158 of SEQ ID NO:2; (m) at least 30 contiguous amino acids of SEQ ID NO:2; (n) the complete endokine alpha amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97640; (o) the complete endokine alpha amino acid sequence encoded by the cDNA clone in ATCC Deposit No. 97640, minus the N-terminal methionine residue; (p) the extracellular domain of the endokine alpha encoded by the cDNA clone in ATCC Deposit No. 97640; and (q) at least 30 contiguous amino acids of the endokine alpha encoded by the cDNA clone in ATCC Deposit No. 97640; wherein said antibody inhibits TNF-α induction.